P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

March 2012

Features

Tech Trends

FDA Weighs Updating Its Bar-Code Mandate

Hospital Pharmacies Worry About Implementation

Stephen Barlas

Controversies in Practice

Interviews With Two Women’s Health Experts on the Use of Estrogen Therapies

Two gynecologists share their views on hormone therapy.
Maribeth Maher

Multiple Sclerosis Review

Patients with relapsing–remitting multiple sclerosis now have a number of options—eight FDA-approved drugs, medications that relieve symptoms, and off-label therapies. Promising new agents are also under development.
Marvin M. Goldenberg, PhD, RPh, MS

Meeting Highlights

Cardiovascular Research Technologies 2012

Clopidogrel (Plavix) is prescribed more often than the newer antiplatelet agents ticagrelor (Brilinta) and prasugrel (Effient). Topics include the reasons behind the slow adoption of these two drugs, the best use of antiplatelet therapy, and considerations for switching patients from clopidogrel to the newer agents.
Walter Alexander

P&T Snapshot

Biologics and Specialty Pharmacy Health Care Survey

Implications for P&T Committees

Responding employers were generally uninformed about the benefits of biologics. Developing programs to help companies understand these products should enable them to manage costs more effectively and result in improved health outcomes for their insured employees.
Cheryl Larson, BA; Margaret Rehayem, MA; F. Randy Vogenberg, RPh, PhD; and Larry Boress, MPA

Departments

Medication Errors

Tall Man Letters Are Gaining Wide Acceptance

Tall man (capital) letters help prevent confusion of look-alike drug names.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Congress Is Likely to Approve Generic Drug User Fees

Action Should Spur Faster FDA Approvals

Congress may soon approve two new user-fee programs.
Stephen Barlas

Pharmaceutical Approval Update

Bydureon injection for diabetes, Onfi tablets for seizures in patients with Lennox–Gastaut syndrome, and Voraxaze injection for eliminating excessively high methotrexate levels in patients with renal impairment
Marvin M. Goldenberg, PhD, RPh, MS

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Drug Forecast

Roflumilast (Daliresp)

A Novel Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease

Jordan Baye, PharmD, MA